Your browser is no longer supported. Please, upgrade your browser.
Settings
CTSO Cytosorbents Corporation daily Stock Chart
CTSO [NASD]
Cytosorbents Corporation
Index- P/E- EPS (ttm)-0.56 Insider Own3.50% Shs Outstand32.70M Perf Week-3.35%
Market Cap226.28M Forward P/E- EPS next Y-0.21 Insider Trans-2.08% Shs Float28.61M Perf Month-7.11%
Income-17.20M PEG- EPS next Q-0.18 Inst Own27.10% Short Float8.67% Perf Quarter-0.72%
Sales22.50M P/S10.06 EPS this Y-75.90% Inst Trans-0.23% Short Ratio19.42 Perf Half Y-32.09%
Book/sh0.53 P/B13.06 EPS next Y60.40% ROA-52.90% Target Price15.30 Perf Year-8.95%
Cash/sh0.69 P/C10.10 EPS next 5Y- ROE-94.30% 52W Range6.70 - 14.95 Perf YTD-14.36%
Dividend- P/FCF- EPS past 5Y5.60% ROI-55.60% 52W High-53.72% Beta1.53
Dividend %- Quick Ratio4.20 Sales past 5Y56.20% Gross Margin66.70% 52W Low3.27% ATR0.30
Employees125 Current Ratio4.30 Sales Q/Q32.60% Oper. Margin-69.30% RSI (14)37.50 Volatility4.27% 4.07%
OptionableYes Debt/Eq0.59 EPS Q/Q-55.80% Profit Margin-76.50% Rel Volume0.37 Prev Close6.92
ShortableYes LT Debt/Eq0.55 EarningsMar 07 AMC Payout- Avg Volume127.77K Price6.92
Recom- SMA20-5.60% SMA50-10.30% SMA200-29.69% Volume4,682 Change-0.02%
Aug-08-17Reiterated Maxim Group Buy $10 → $12
Oct-26-16Initiated Aegis Capital Buy
May-24-16Initiated Maxim Group Buy $8
Oct-29-15Upgrade WBB Securities Speculative Buy → Buy $13 → $13
May-12-15Reiterated MLV & Co Buy $28 → $21
Apr-01-15Reiterated MLV & Co Buy $28 → $30
Mar-05-15Initiated MLV & Co Buy $30
Feb-25-15Initiated WBB Securities Speculative Buy $13
Jan-27-15Reiterated H.C. Wainwright Buy $1 → $12
Apr-24-19 07:08AM  CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences PR Newswire
Apr-08-19 05:30AM  CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London PR Newswire
Mar-25-19 07:10AM  Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor PR Newswire
Mar-11-19 04:20PM  CTSO: Q4 2018: Product Sales +27%, Expenses Jump In Part Due to Investments Aimed at Further Accelerating Growth Zacks Small Cap Research
Mar-07-19 10:00PM  Cytosorbents Corp (CTSO) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:15PM  CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018 PR Newswire
Mar-06-19 07:00AM  CytoSorbents to Present at the Cowen 39th Annual Health Care Conference PR Newswire
Mar-05-19 07:10AM  CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands PR Newswire
Feb-28-19 07:00AM  CytoSorbents to Report Fiscal 2018 Operating and Financial Results PR Newswire
Feb-25-19 07:08AM  CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference PR Newswire
Feb-05-19 07:00AM  CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference PR Newswire
Feb-04-19 03:00PM  CTSO: DSMB Recommends Continuance of REMOVE Study: Has several important implications Zacks Small Cap Research +5.24%
06:58AM  CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial PR Newswire
Feb-01-19 11:30AM  LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index ACCESSWIRE
Jan-23-19 07:45AM  Detailed Research: Economic Perspectives on Shell Midstream Partners, Interface, National Western Life Group, TPG Specialty Lending, Francesca's, and Cytosorbents What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-22-19 07:08AM  CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care PR Newswire -5.71%
Jan-18-19 02:22PM  Is Cytosorbents Corporations (NASDAQ:CTSO) CEO Pay Fair? Simply Wall St.
Jan-07-19 03:45PM  CTSO: Q4 / FY 2018: Record Product Sales in Q4, Jumps 51% in 2018 Zacks Small Cap Research +6.34%
09:20AM  CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results PR Newswire
Jan-04-19 07:00AM  CytoSorbents To Highlight Progress at Biotech Showcase 2019 PR Newswire +6.06%
Dec-21-18 08:45AM  CytoSorbents To Receive $619,546 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program PR Newswire -7.36%
Dec-10-18 02:13PM  Is Cytosorbents Corporations (NASDAQ:CTSO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-26-18 07:00AM  CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-19-18 07:08AM  CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte's 2018 Technology Fast 500 PR Newswire
Nov-12-18 07:08AM  CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week PR Newswire
Nov-09-18 09:45AM  CTSO: Q3: Another Solid Quarter. Financials In-Line, REFRESH II Enrollment Accelerating Zacks Small Cap Research -8.03%
08:00AM  Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-06-18 06:25PM  CytoSorbents: 3Q Earnings Snapshot Associated Press
04:15PM  CytoSorbents Reports Third Quarter 2018 Financial Results PR Newswire
Nov-01-18 02:22PM  Cytosorbents Corporation (NASDAQ:CTSO) Is Trading At A 28.36% Discount Simply Wall St.
Oct-31-18 07:00AM  CytoSorbents to Report Q3 2018 Operating and Financial Results PR Newswire
Oct-18-18 09:30AM  CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences PR Newswire
Oct-15-18 07:45AM  Detailed Research: Economic Perspectives on LifePoint Health, Carter's, Lincoln Electric, Cytosorbents, ServiceNow, and Chimera Investment What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-03-18 07:10AM  CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-20-18 07:55AM  CytoSorb® Assigned Dedicated Procedure Code in Switzerland PR Newswire
Sep-14-18 11:33AM  Do You Know Who Else Invests In Cytosorbents Corporation (NASDAQ:CTSO)? Simply Wall St.
Sep-13-18 07:08AM  World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research PR Newswire
Sep-05-18 09:45AM  CTSO: FDA Approves REFRESH-2 Protocol Amendment Zacks Small Cap Research
Sep-04-18 07:05AM  CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA PR Newswire
Aug-29-18 06:03PM  Cytosorbents Stock Could Score Big With Its Blood-Filtering Technology InvestorPlace +6.99%
Aug-21-18 05:49PM  Edited Transcript of CTSO earnings conference call or presentation 2-Aug-18 8:45pm GMT Thomson Reuters StreetEvents
09:06AM  CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend Blood Transfusion Filter PR Newswire
Aug-08-18 12:30PM  CTSO: Q2 Product Sales Beat Big. New Catalysts Come Online. Moving PT to $15/share Zacks Small Cap Research
08:10AM  Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-03-18 05:09AM  CytoSorbents: 2Q Earnings Snapshot Associated Press -9.88%
Aug-02-18 04:15PM  CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018 PR Newswire
02:45PM  CytoSorbents Corporation to Host Earnings Call ACCESSWIRE
Jul-31-18 07:08AM  CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide PR Newswire
Jul-26-18 07:00AM  CytoSorbents to Report Q2 2018 Operating and Financial Results PR Newswire
Jul-09-18 08:00AM  Aferetica and CytoSorbents Debut the PerLife System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society PR Newswire +6.52%
Jun-26-18 07:08AM  CytoSorbents Added to the Russell 2000 and Russell 3000 Indexes PR Newswire
Jun-12-18 07:08AM  CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility PR Newswire
Jun-04-18 07:30AM  CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-21-18 09:26AM  CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference PR Newswire
May-14-18 07:08AM  CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use PR Newswire
May-09-18 05:40PM  CTSO: Q1 2018 Update: Product Sales New Record. REFRESH 2 Enrollment Should Pick Up Steam. REMOVE Already Ramping Zacks Small Cap Research
May-08-18 06:27PM  CytoSorbents: 1Q Earnings Snapshot Associated Press
04:15PM  CytoSorbents Reports Strong First Quarter 2018 Financial Results PR Newswire
May-07-18 09:47AM  What You Must Know About Cytosorbents Corporations (NASDAQ:CTSO) Financial Strength Simply Wall St.
May-04-18 07:40AM  New Research: Key Drivers of Growth for Lincoln Electric, Cytosorbents, Materion, Fortune Brands Home & Security, Washington Real Estate Investment Trust, and CPB Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
May-02-18 07:00AM  CytoSorbents to Report Q1 2018 Operating and Financial Results PR Newswire
Apr-24-18 07:08AM  CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery PR Newswire
Apr-09-18 01:57AM  CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich PR Newswire
Apr-04-18 06:55AM  CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank PR Newswire
Mar-28-18 09:17AM  CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference PR Newswire
Mar-19-18 10:15AM  CTSO: Q4 2017 Update: Q4 / FY Product Sales +64% / 63%, Product Margin Jumps 900bp. FDA Pivotal Study Underway Zacks Small Cap Research
07:45AM  Research Report Identifies Matrix Service, Barrett Business Services, Materion, C&J Energy Services, YRC Worldwide, and Cytosorbents with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-12-18 07:00AM  CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference PR Newswire
Mar-08-18 04:15PM  CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017 PR Newswire
01:30PM  CytoSorbents Corporation to Host Earnings Call ACCESSWIRE
Mar-01-18 08:00AM  CytoSorbents to Report Fiscal 2017 Operating and Financial Results PR Newswire
Feb-26-18 07:10AM  CytoSorbents to Participate at the BTIG Healthcare Conference PR Newswire
Feb-15-18 06:55AM  CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia PR Newswire
Feb-13-18 05:10PM  CytoSorbents' CEO on flu epidemic Yahoo Finance Video
Feb-06-18 07:08AM  CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference PR Newswire
Feb-01-18 07:20AM  New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification PR Newswire
Jan-12-18 11:45AM  CTSO: Q4 Preannouncement, Our Initial Thoughts on REFRESH II Zacks Small Cap Research
Jan-09-18 08:10AM  New Research: Key Drivers of Growth for Merit Medical, NETGEAR, Hancock Holding, Alexandria Real Estate Equities, Cytosorbents, and Stepan Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-08-18 07:15AM  CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter PR Newswire +6.38%
Jan-03-18 07:05AM  CytoSorbents To Provide Corporate Update at Biotech Showcase 2018 PR Newswire
Jan-01-18 09:13AM  CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-28-17 08:45AM  Streetwise Reports Examines an Immunotherapy Firm That Received a Green Light from FDA for Pivotal Trial GlobeNewswire
Dec-21-17 02:58PM  CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application PR Newswire +6.50%
Dec-19-17 02:00PM  CTSO: Large Infective Endocarditis Clinical Study Could Be Win-Win for CytoSorbents Zacks Small Cap Research
07:00AM  CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program PR Newswire
Dec-11-17 08:10AM  German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial PR Newswire
Dec-08-17 12:36PM  ETFs with exposure to CytoSorbents Corp. : December 8, 2017 Capital Cube
Nov-29-17 07:00AM  CytoSorbents to Present at the LD Micro Main Event Investor Conference PR Newswire
Nov-23-17 06:31PM  Is Cytosorbents Corporations (CTSO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-21-17 11:00AM  CTSO: Germany Reimbursement Rebounds, Drives Strong Record Product Zacks Small Cap Research
Nov-09-17 06:25PM  CytoSorbents reports 3Q loss Associated Press
04:17PM  CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017 PR Newswire
12:50PM  CytoSorbents Corporation to Host Earnings Call ACCESSWIRE
12:29PM  ETFs with exposure to CytoSorbents Corp. : November 9, 2017 Capital Cube
07:15AM  CytoSorbents Recognized on Deloitte's 2017 Technology Fast 500 as One of the Fastest Growing Companies in North America PR Newswire
Nov-02-17 08:00AM  CytoSorbents to Report Q3 2017 Operating and Financial Results PR Newswire
Nov-01-17 07:05AM  CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia PR Newswire
Oct-30-17 11:38AM  ETFs with exposure to CytoSorbents Corp. : October 30, 2017 Capital Cube
Oct-27-17 09:00AM  CTSO: Additional Evidence Supporting CytoSorb Use in Sepsis, Cardiac Surgery Zacks Small Cap Research
Oct-20-17 10:09AM  ETFs with exposure to CytoSorbents Corp. : October 20, 2017 Capital Cube
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol, a development stage blood purification technology; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chan Phillip P.President and CEODec 07Option Exercise2.1089,337187,608527,618Dec 11 02:06 PM
Chan Phillip P.President and CEODec 07Sale9.3724,337228,026503,281Dec 11 02:06 PM
Chan Phillip P.President and CEOSep 07Option Exercise2.102,7315,735449,699Sep 07 09:55 PM
Chan Phillip P.President and CEOSep 07Sale14.112,73138,534438,281Sep 07 09:55 PM
Chan Phillip P.President and CEOSep 06Option Exercise2.102,9006,090446,968Sep 07 09:55 PM
Chan Phillip P.President and CEOSep 06Sale14.752,90042,775441,012Sep 07 09:55 PM
Chan Phillip P.President and CEOSep 05Option Exercise2.095,78712,093444,068Sep 07 09:55 PM
Chan Phillip P.President and CEOSep 05Sale14.855,78785,937443,912Sep 07 09:55 PM
Kraus AlDirectorAug 30Option Exercise3.5526,00092,400151,046Aug 31 08:19 PM
Kraus AlDirectorAug 30Sale14.4726,000376,282125,046Aug 31 08:19 PM
Capponi VincentChief Operating OfficerAug 29Option Exercise3.4520,00069,000352,768Aug 31 03:35 PM
Capponi VincentChief Operating OfficerAug 29Sale14.0020,000280,000332,768Aug 31 03:35 PM
BLOCH KATHLEEN P.Chief Financial OfficerAug 28Option Exercise2.8810,00028,750260,004Aug 30 03:59 PM
Capponi VincentChief Operating OfficerAug 28Option Exercise3.759,56535,869342,333Aug 30 04:01 PM
Capponi VincentChief Operating OfficerAug 28Sale13.009,565124,345332,768Aug 30 04:01 PM
BLOCH KATHLEEN P.Chief Financial OfficerAug 28Sale13.5010,000135,000250,004Aug 30 03:59 PM
Capponi VincentChief Operating OfficerAug 03Option Exercise3.457,60026,220340,368Aug 06 05:21 PM
BLOCH KATHLEEN P.Chief Financial OfficerAug 03Option Exercise2.8810,00028,750260,004Aug 07 03:18 PM
Capponi VincentChief Operating OfficerAug 03Sale13.087,60099,408332,768Aug 06 05:21 PM
BLOCH KATHLEEN P.Chief Financial OfficerAug 03Sale12.5410,000125,364250,004Aug 07 03:18 PM
Capponi VincentChief Operating OfficerAug 02Option Exercise3.452,8359,781335,603Aug 06 05:21 PM
Capponi VincentChief Operating OfficerAug 02Sale13.002,83536,855332,768Aug 06 05:21 PM
Capponi VincentChief Operating OfficerJun 15Option Exercise1.3948,63367,374367,983Jun 18 06:14 PM
Capponi VincentChief Operating OfficerJun 15Sale12.008,633103,596347,983Jun 18 06:14 PM
Capponi VincentChief Operating OfficerJun 14Option Exercise3.7511,36742,626319,350Jun 18 06:14 PM
Capponi VincentChief Operating OfficerJun 14Sale12.0011,367136,404356,616Jun 18 06:14 PM
Capponi VincentChief Operating OfficerMay 17Option Exercise1.8328,00051,100345,551May 18 02:47 PM
Capponi VincentChief Operating OfficerMay 17Sale10.0028,000280,000317,551May 18 02:47 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 16Option Exercise4.6912,40058,156265,704May 16 09:32 PM
Capponi VincentChief Operating OfficerMay 16Option Exercise0.884,8464,240322,397May 18 02:45 PM
Capponi VincentChief Operating OfficerMay 16Sale9.004,84643,614317,551May 18 02:45 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 16Sale9.0012,400111,600253,304May 16 09:32 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 15Option Exercise4.6912,40058,156265,704May 16 09:31 PM
Capponi VincentChief Operating OfficerMay 15Option Exercise2.737,15419,560324,705May 17 12:53 PM
Capponi VincentChief Operating OfficerMay 15Sale9.007,15464,386317,551May 17 12:53 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 15Sale8.7512,400108,500253,304May 16 09:31 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 14Option Exercise2.9010,00029,000263,304May 16 02:01 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 14Sale8.5010,00085,000253,304May 16 02:01 PM